Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 2 of 89 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 3 of 89 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page ii of ii comparison will be made at 18 0 days post -treatment  for the secondary 
endpoint. T o reduce potential bias associated with evaluating only treated -
subject photographs , images of untreated individuals,  collected at two time 
points, w ill also be included for blinded, independent photographic review.  
Study subjects w ill have a pproximately 4 in-office study visits, including 
screening, baseline/treatment, a Day 90 (± 7 days) post -treatment visit , and a 
Day 180 (± 14 days) post -treatment visit. Follow -up telephone calls will 
occur at 3 days (± 1 day) , 14 days ( ± 3 days),  28 days (+ 3 days) , 120 days 
(± 7 days) , and 150 days (± 7 days) after Octave-Ultherapy treatment.  
Expected study duration is approximately 8 months from screening of the 
first subject until final follow -up of the last subject. In Stage  1, an initial 
cohort of 10 subjects will be enrolled, safety data will be assessed up to 
Week  2, and subjects will participate until the Stage 1 study end at Day 90. 
In Stage  2, all enrolled subjects will participate until study end at Day  90 or 
Day 180 if reconsented for extended participation. The planned duration of 
participation for individual subjects is up to 30 weeks, including up to 
21 days for screening,  1 day for treatment, and 90 or 180 days for follow -up. 
Number of 
Study Subjects   Approximately 113 subjects are planned for screening to allow for 
90 enrolled/treated subjects and 80 evaluable subjects in this study.  In 
Stage 1, 10 subjects w ill be enrol led, w hile all other subjects w ill be enrolled 
in Stage  2. 
Main  Inclusion/  
Exclusion Criteria  Key inclusion criteria are as follow s: 
−Healthy female aged 35 to 65 years at the time of screening.
−Moderate to severe fine lines, w rinkles , laxity , and crepiness  of the
décolleté that is amenable to improvement with non-invasiveintervention and is not severe enough for surgical intervention.
Key exclusion criteria are as follows:  
−Presence of an active systemic or local skin disease that may affectwound healing.
−Scarring in area(s) to be treated.
−Active implants  (e.g., pacemakers or defibrillators), ports, or metallic
implants in area(s) to be treated.
−Breast implants or is planning to receive breast implants during the
study.
−Inability to take pre -treatment medications due to a pre-existing
condition, medication allergy, or medical issue that, at the discretion of
the treating investigator, is contraindicated.

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 6 of 89 3 TABLE OF CONTENTS 
1 TITLE PAGE ...................................................................................................... 1  
2 SYNOPSIS  ............................................................................................................ i  
3 TABLE OF CONTENTS ..................................................................................... 6  
4 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ..................... 10 
5 ETHICS ............................................................................................................. 12 
5.1 Ethical Conduct of the Study  ............................................................................ 12 
5.2 Informed Consent  ............................................................................................ 12 
5.3 Subject Privacy  ................................................................................................ 13 
5.4 Confidentiality of Subject Information  .............................................................. 13 
6 INTRODUCTION  ............................................................................................. 14 
6.1 Background  ..................................................................................................... 14 
6.2 Study Rational e................................................................................................ 18 
6.3 Potential Benefits and Risks  ............................................................................. 19 
7 STUDY OBJECTIVE AND ENDPOINTS  ........................................................ 21 
7.1 Objective  ......................................................................................................... 21 
7.2 Endpoints  ........................................................................................................ 21 
7.2.1  Effectiveness Endpoints .............................................................................. 21 
7.2.1.1  Primary Effectiveness Endpoint ............................................................ 21 
7.2.1.2  Secondary Effectiveness Endpoint  ........................................................ 21 
7.2.2  Safety Endpoints  ........................................................................................ 22 
7.2.2.1  Secondary Safety Endpoint  ................................................................... 22 
8 CLINICAL INVESTIGATION PLAN.............................................................. 24 
8.1 Overview of Study Design ................................................................................ 24 
8.2 Discussion of Study Design, Including the Choice of Control Groups  ................ 25 
9 STUDY POPULATION AND RESTRICTIONS  .............................................. 26 
9.1 Number of Subjects and Sites  ........................................................................... 26 
9.2 Selection of Subject Population  ........................................................................ 26 
9.2.1  Inclus ion Cr iter ia ........................................................................................ 27 
9.2.2  Exclus ion Cr iter ia  ...................................................................................... 28 
9.2.4  Subject Enrollment  ..................................................................................... 31 
9.2.5  Screen Failures ........................................................................................... 31 
9.2.6  Removal of Subjects from Therapy or Assessment  ...................................... 32 
9.2.6.1  Treatment Discontinuation  ................................................................... 32 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 7 of 89 9.2.6.2  Subject Withdrawal or Discontinuation  ................................................ 32 
9.2.6.3  Provision of Care for Subjects after Study Discontinuation  ................... 33 
9.2.7  Suspension or Premature Termination of a Study Site  .................................. 33 
9.2.8  Suspension or Premature Termination of the Study ...................................... 34 
9.2.9  Subject Completion .................................................................................... 35 
9.2.10  End of Study  .............................................................................................. 35 
10 STUDY DEVICE AND TREATMENT OF SUBJECTS ................................... 36 
10.1  Description of Study Device  ............................................................................. 36 
10.1.1  Mechanism of Action  ................................................................................. 37 
10.1.2  Operating Information  ................................................................................ 37 
10.2  Instructions for Use and Administration  ............................................................ 39 
10.3  Methods of Assigning Subjects to Treatment Groups  ........................................ 39 
10.4  Blinding Procedures  ......................................................................................... 40 
10.5  Study Treatment ............................................................................................... 40 
10.5.1  Planned Treatment Procedure and Administration  ....................................... 40 
10.5.1.1  Pre-Treatment Assessments  .................................................................. 40 
10.5.1.2  Pre-Treatment Medications and Procedure  .......................................... 40 
10.5.1.3  Treatment Region and Administration Procedure .................................. 42 
10.5.2  Selection and Timing of Treatment for Each Subject  ................................... 44 
10.5.3  Treatment Interruption and Modification ..................................................... 44 
10.6  Prior and Concomitant Therapy  ........................................................................ 44 
10.7  Study Supplies and Packaging of Treatment Supplies  ........................................ 45 
10.8  Receipt, Storage, Dispensing, and Return/Disposal  ........................................... 45 
10.9  Device Accountability Procedures  .................................................................... 45 
10.10  Treatment Compliance  ..................................................................................... 46 
10.11  Duration of Study ............................................................................................. 46 
11 STUDY PROCE DURES .................................................................................... 47 
11.1  Vis it Sche dule .................................................................................................. 47 
11.1.1  Scheduled V is its ......................................................................................... 48 
11.1.2  Unscheduled Visits ..................................................................................... 48 
11.2  Study Assessments and Definitions ................................................................... 49 
11.2.1  Effectiveness Assessments.......................................................................... 49  
11.2.1.1  Standardized 2D Photographs .............................................................. 49 
11.2.2  Safety Assessments .................................................................................... 52 
11.2.2.1  Adverse Events (AEs)/Serious Adverse Events (SAEs)  ........................... 52 
11.2.3  Additional Data Collected ........................................................................... 54 
12 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  .................. 56 
12.1  Definition of an Adverse Event (AE)  ................................................................ 56 
12.1.1  Details of an AE  ......................................................................................... 56 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 8 of 89 12.1.2  Reporting and Handling of an AE  ............................................................... 56 
12.1.3  Severity Grading for an AE  ........................................................................ 57 
12.1.4  Causal Relationship of an AE with an Investigational Medical Device  ......... 57 
12.1.5  Outcome Categories for an AE  ................................................................... 58 
12.2  Definition of a Serious Adverse Event (SAE) .................................................... 58 
12.2.1  Details of an SAE ....................................................................................... 59 
12.2.2  Reporting and Handling of an SAE  ............................................................. 59 
12.3  Definition of an Adverse Device Effect (ADE)  ................................................. 60 
12.4  Definition of a Serious Adverse Device Effect (SADE)  ..................................... 61 
12.4.1  Definition of an Anticipated Serious Adverse Device Effect (ASADE)  ........ 61 
12.4.2  Definition of an Unantici pated Adverse Device Effect (UADE)  ................... 61 
12.5  Definition of Device Deficiency  ....................................................................... 61 
12.6  Definit ion of Technica l Compla int .................................................................... 61 
12.6.1  Reporting and Handling of Device Deficiencies  .......................................... 62 
12.8  Reporting of Pregnancy  .................................................................................... 63 
13 STATISTICAL METHODS  .............................................................................. 64 
13.1  Estimation of Sample Size ................................................................................ 64 
13.2  Randomization ................................................................................................. 64 
13.3  Populations for Analysis ................................................................................... 64 
13.4  Analysis of Study Data ..................................................................................... 65 
13.4.1  Effectiveness Analyses  ............................................................................... 65 
13.4.1.1  Primary Effectiveness Endpoint ............................................................ 65 
13.4.1.2  Secondary Effectiveness Endpoint  ........................................................ 66 
13.4.2  Safety Analyses .......................................................................................... 66 
13.4.2.1  Secondary Safety Endpoint  ................................................................... 67 
13.4.3  Other Subject Data ..................................................................................... 68 
13.5  Specia l Stat ist ica l/A nalyt ica l Issues  .................................................................. 69 
13.5.1  Subject Discontinuation and Missing Data  .................................................. 69 
13.5.2  Interim Analysis  ......................................................................................... 69 
14 ADMINISTRATIVE PROCEDURES ............................................................... 70 
14.1  Study Monitoring  ............................................................................................. 70 
14.2  Data Qu ality Assurance  .................................................................................... 70 
14.2.1  Standardization Procedures ......................................................................... 70 
14.2.2  Data Management  ...................................................................................... 70 
14.2.3  Data Review and Clarification Procedures ................................................... 71 
14.2.4  Auditing ..................................................................................................... 72 
14.3  Record Retention  ............................................................................................. 72 
14.4  Publica tion Policy  ............................................................................................ 73 
14.5  Financ ia l D isclosure ......................................................................................... 74 
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 9 of 89 14.6  Investigator Compliance ................................................................................... 74 
15 REFERENCES .................................................................................................. 75 
16 APPENDICES  ................................................................................................... 77 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 12 of 89 5 ETHICS 
5.1 Ethical Conduct of the Study  
This study will be performed in accordance with the principles outlined in the Declaration 
of Helsinki and in compliance with the  International Council for Harmoni sation of 
Technical Requirements for Pharmaceuticals for Human Use’s Good Clinical Practice 
(ICH-GCP) , EN ISO 14155, the Code of Federal Regulations  (CFR), and any applicable 
regional or national laws and regulations. The study will adhere to all applicable subject privacy requirements.  
All required approvals, favorable opinions, or additional requirements of the appropriate 
Independent Ethics Committee (IEC), Institutional Review Board (IRB),  or other 
regulatory authority will be obtained prior to initiation of the trial.  
The investigator  and all study personnel will conduct the study in compliance with this 
protocol. The investigator will ensure all personnel involved in the conduct of this study 
are qualified to perform the assigned study responsibilities. Investigators will adhere to al l 
applicable study reporting requirements.  
5.2 Informed Consent  
Verbal and w ritten informed consent must be obtained from every subject prior to the 
initiation of any screening or study procedures. The investigator will follow a standard process for obtaining consent that complies with all applicable regulatory requirements. 
If applicable, a certified , local -language  translation of the informed consent form ( ICF) 
will be provided.  
If the ICF is amended during the study, the investigator must follow all applicab le 
regulatory requirements pertaining to approval of the amended ICF by the IEC/IRB and 
use of the amended form . Ongoing subjects will be required to re -confirm consent by 
signing the amended form.  
The original and any amended signed and dated ICF (s) must be retained at the study site ; 
a copy of the signed and dated ICF(s) must be given to the subject.  
During the study, the subject will be informed if information becomes available that may 
be relevant to the subject’s willingness to continue participation in the study. Each ICF will include contact information (with a phone number) the subject should use  to communicate 
any medical concerns 24 hours a day.  The subject, however, is free to withdraw consent at 
any time and for any reason, whether expressed or not.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 13 of 89 5.3 Subject Privacy  
The subject will be informed of procedures to protect subject privacy. Under US  federal 
law (the Privacy Rule), any protected health information (PHI) that is created or obtained 
during this study cannot be used or disclosed without permission. The currently designated statistical contract research organization (CRO) processes subjec t data in accordance with 
the data -protection provisions set forth in the German Federal Data Protection Act 
(Bundesdatenschutzgesetz), specifically in the version applicable as of 25-MAY -2018, and 
in the European-focused General Data Protection Regulation  law (GDPR) . 
Informed consent on data processing will be obtained in writing directly from the subject 
before recording of any data. Authorization to use and disclose PHI will be obtained in 
writing directly from the subject before recording of any data. R ecorded data will be 
pseudonymized before transferring to authorized individuals. The  investigator will 
maintain source documents linking  unique subject numbers with subject names (e.g., in 
case of emergencies).  
At the conclusion of the study, subject photographs will be stored and archived 
electronically by the sponsor  and the study site. Photographs allowing identification of the 
subject will be published only if the subject has given written permission.  
5.4 Confidentiality of Subject Information 
Subject pseudoanonymity is to be maintained during the study. Subjects will be identified by a unique subject  number on all study documentation. Health information that could  
identify the subject (i.e., PHI) must be maintained in strict confidence by the investigator 
to the extent permitted by applicable laws and regulations.  Subjects must sign an 
authorization to allow PHI to be disclosed to the sponsor and anyone working on behalf of the sponsor, the IRB/IEC, or regulatory authorities.  
Confidentialit y will also be ma intained for any medical information obtained from the 
subject during study participation. At a subject’s request, the subject’s medical information 
may be provided to the subject’s personal physician or other appropriate medical personnel.  
If the results of the investigation are published, the subject’s identity will remain 
confidential.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 14 of 89 6 INTRODUCTION 
6.1 Background 
Many factors contribute to the natural aging process during which an individual’s skin 
gradually loses its youthful appearance. Aging skin is chara cterized by loss of volume, 
decreased elasticity, and increased laxity. Various aesthetic techniques have been used in 
an attempt to reverse or slow the aging process. As such, i ndividuals are increasingly 
undergoing facial rejuvenation procedures ; after t reatment , they often notice the improved 
appearance of the face is in contrast with that of the untreated aging neck and chest. The 
chest and neck are exposed to substantial ultraviolet ( UV) radiation  and both regions tend 
to demonstrate photoaging. Additi onally, the chest skin of females is vulnerable to the 
mechanical stress of the weight and movement of the breasts. [1] Aging of the  skin in the 
décolleté region manifests as atrophy, laxity, wrinkles, and dyspigmentation.  
Special anatomic considerations  exist when treating the skin of the décolleté. The skin in 
this area is thinner than some areas of the face[2 ] as well as the arms and legs .[1] 
Additionally, there are over 13 times fewer hair follicles on the chest than on the late ral 
forehead. [3] This difference in pilosebaceous units contributes to the slower healing and 
increased risk of scarring with aesthetic treatments of the décolleté region, particularly ablative ones .[4] Modalities used to treat signs of aging in the décolleté region include 
neurotoxins, fillers, chemical peels, intense pulsed light, and non-ablative and ablative 
lasers. [5] 
Various energy-delivery devices , designed to create thermal injur y to stimulate  fibroblast 
synthes is and collagen production (e.g., fractionated ablative lasers, radiofrequency 
devices, fractional infrared devices), have been developed. [6] While these energy -based 
devices have de monstrated tightening effects on superficial layers of the skin,  ultrasound 
energy can cause deeper skin -tightening effects by delivering focused energy to the dermis. 
Furthermore, ultrasound-energy use is associated with fewer adverse post-treatment effects 
when compared to epidermal treatments, due to its penetration of the deeper layers of skin while  leaving the  epidermal layers and intervening skin tissues unaffected .[7] This 
characteristic of microfocused ultrasound is particularly beneficial in patients of higher 
Fitzpatrick skin types ( FST III to VI)[8 ], as melanocytes and melanin are superficial to the 
treatment location. As a result, micr ofocused ultrasound tends not to affect skin pigment 
and is safe for use in all FST.[9] 
The Ulthera System is a non-invasive, dermatological, aesthetic treatment that is FDA 
cleared to lift the eyebrow (K072505), lift (K121700) and improve the appearance 
(K180623) of lax submental and neck tissue, and reduce wrinkles and lines in the décolleté 
(K134032). In previous clinical trials, the Ulthera System has demonstrated safety and 
effectiveness as a non -invasive aesthetic treatment. Ultherapy utilizes microfocused 
ultrasound energy with visualization (MFU -V) to create thermal coagulation points (TCPs) 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 16 of 89 
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 17 of 89 
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 18 of 89 6.2 Study 
Rationale  
The current confirmatory study is designed to demonstrate the safety and effectiveness of 
the Octave System for i mproving lines and wrinkles of the décolleté. Analogous to the face 
and neck, changes in décolleté -skin tone and texture, including lines and wrinkles,  occur 
with age , creating a concern for many individuals.  Additio nally, the chest skin of females 
is vulnerable to the mechanical stress of the weight and movement of the breasts, which 
can cause dynamic changes in the skin. [1] Ultherapy targets lines and wrinkles of the 
décolleté and offers a non-invasive approach to improving the aesthetic appearance of this region. Subjects with moderate to severe fine lines, wrinkles, laxity, and crepiness of the décolleté that is amenable to improvement with non-invasive intervention and is not severe 
enough for surgical intervention will be treated. Subjects will receive one Octave-
Ultherapy tr eatment of the décolleté tissue and will be followed for 90 or 180 days. 
Previous studies have shown improvement in the aesthetic appearance of the décolleté region after DeepSEE Ultherapy treatment as early as  90-days post -treatment
; thus, subjects will be followed 
for the same length of time  for the primary endpoint . Subjects will be treated with two 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 20 of 89 because these AEs are reported voluntarily from a population of uncer tain size, it is not  
always possible to reliably estimate their frequency or establish a causal relationship with 
the Ulthera DeepSEE System.  
In clinical trials with the first-generation Ulthera DeepSEE system, no device - or 
procedure -related serious adver se events (SAEs) were observed , and reported adverse 
events ( AEs) were generally expected, mild in nature, and short in duration. [7, 15-17 ] 
Long-term follow -up studies confirmed the favorable safety profile of the Ulthera 
DeepSEE system with primarily mild, treatment -related side effects. [10] 
Risks of Ultherapy on the second-generation Octave System will be minimized or reduced 
by training the investigat iona l sites and monitoring the subject during the treatment 
procedure , with careful observation of the subject’s pain and skin response to treatment. 
Previous  clinical studies with the Ulthera DeepSEE System have shown the sensory 
response was tolerable from both the subject’s and investigator’s perspective .[10] 
Discomfort was transient, and acute pain resolved within 3 0 minutes. If the subject is 
uncomfortable during Octave System  treatment, the treating investigator has the option to 
utilize additional measures to improve tolerability, including additional/different pain 
medication (e.g., see Section  10.5.1.2). If treatment remains intolerable after 
implementation of mitigation measures , the investigator or delegated study clinician must 
stop administering treatment , for the subject’s safety, and the subject will be followed for 
AEs throughout the study’s duration. In the case of an AE report, the subject will be 
followed until the subject’s last study visit , until the AE is resolved or stabilized, the subject 
is lost to follow -up, or some other resolution of the event  occurs.  
Considering all risks and benefits of Ultherapy on the Octave System, the potential benefits 
to physicians and subjects seeking treatment outweigh the potential risks. The  benefit/risk 
ratio of the device is considered acceptable when used on subjects seeking improvement of lines and wrinkles of the décolleté.  
Additional information on device - and procedure -related contraindications, warnings, and 
precautions can be found in the current version of the Octave System IFU  
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 21 of 89 7 STUDY OBJECTIVE  AND ENDPOINTS 
7.1 Objective  
The objective of this study is to demonstrate the safety and effectiveness of the Octave 
System for i mproving lines and wrinkles of the décolleté. 
7.2 Endpoints  
7.2.1  Effectiveness Endpoints  
7.2.1.1  Primary Effectiveness Endpoint  
• Proportion of treated subjects with improvement in lines and wrinkles of the décolleté  
by comparing photographs taken at Day 90 (post -treatment) with baseline (pre -
treatment)  photographs . 
o Improvement is concluded if at least two of three independent, blind ed 
evaluators  assess the Day 90 standardized, photographic  images as improved 
compared to baseline  photographic images . 
o The success criterion is defined by achieving simultaneously a point estimate 
≥ 65% and a lower bound of the one -sided 95% Wilson confidence interval 
> 50% for the proportion of treated  subjects with improvement . 
7.2.1.2  Secondary  Effectiveness Endpoint  
• Proportion of treated subjects with improvement in lines and wrinkles of the décolleté  
by comparing photographs taken at Day 180 (post -treatment) with baseline (pre -
treatment)  photographs.  
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 22 of 89 7.2.2  Safety Endpoints  
7.2.2.1  Secondary Safety  Endpoint  
• Incidence of treatment -emergent adverse events ( TEAEs) related to Octave-Ultherapy 
treatment, as reported throughout the study. 
CCI
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 23 of 89 
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 26 of 89 9 STUDY POPULATION AND RESTRICTIONS 
9.1 Number of Subjects and Sites  
Approximately 80 evaluable subjects , who complete the full Ultherapy treatment session 
using the  Octave System, are planned for this study. Assuming a screen failure rate of 20%, 
approximately 113 subjects wil l be screened ; assuming attrition of 10 subjects, 
approximately 90 subjects are planned for enrollment /treatment. All subjects will sign and 
date the ICF before any study-related procedures are undertaken.  
In Stage  1, 10 subjects will be enrolled  at a minimum of two investigational  sites 
(maximum: 6 sites)  in the United States , while all other subjects will be enrolled in Stage  2. 
Number of investigational sites will not exceed ten  in total. During Stage  1, Week  2 safety 
data for the first 10 treated  subjects will be evaluated. All 10 subjects enrolled in Stage  1 
will participate until Stage  1 study end at Day  90. In Stage  2, all other enrolled subjects 
will participate for at least 90 days (±  7 days), with a  maximum duration of 180 days 
(± 14 days)  if reconsented for extended participation. Females of all FST are eligible for 
study participation. In addition, approximately 10% of the enrolled subjects will be  
categorized as F ST IV, V, or VI , and of which 5% will be categorized as FST V or VI . 
Subjects who are enrolled and who do not complete the study will not be replaced. 
Furthermore, the secondary effectiveness endpoin at Day 180 will 
only be assessed among subjects who reconsent at their Day 90 visit for extended study 
participation to Day 180. 
Photographs of approximately 30 untreated individuals , who meet selected appearance 
criteria ( Section  11.2.1.1.1), will be collected at two different time points , between 1 day 
and 1 week apart ; these photographs will be subsequently paired for evaluation by the 
independent, blinded evaluators . 
To confirm the presence of appropriate anatomy at the intended depth of treatment (see 
Inclusion Criterion #3 in Section  9.2.1), the treating investigator will use the Octave 
System’s supplemental imaging mode to visualize the dermal and subdermal layers of 
tissue.  For example, subjects with bone, rather than soft tissue, at the intended treatment 
depth would be considered screen failures and would not be eligible for enrollment. [16] 
Additional information regarding subject enrollment is provided within the sample size 
justification  (Section  13.1). 
9.2 Selection of Subject Population 
The selection criteria have been chosen to identify a suitable population of subjects to investigate the study objectives and to minimize safety concerns in this population.  

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 31 of 89 9.2.4  Subjec
t Enrollment  
Subjects are considered to be enrolled when they provide  informed consent  (i.e., sign the 
ICF), meet all eligibilit y  criteria, or are treated.  
Screen failures are defined in Section  9.2.5. 
9.2.5  Screen Failures  
Subjects who provide  informed consent but who do not meet eligibility criteria  or who 
withdraw consent prior to being treated at the baseline v isit will be defined as screen 
failures. The investigator will maintain all source documentation for all subjects who are 
considered screen failures. Minimal information will be collected in the electronic data 
capture (EDC) system for screen failures, suc h as date of informed consent, demographics, 
and reason for screen failure. In cases when a subject is not meet ing eligibilit y criteria  due 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 32 of 89 to a temporary condition, this subject may be rescreened , at the  discretion of the treating 
investigator , upon resol ution of the temporary condition. 
9.2.6  Removal of Subjects from Therapy or Assessment  
9.2.6.1  T reatment Discontinuation 
If study treatment is discontinued during administration, the investigator will record the 
reason for treatment discontinuation in the study records.  Potential reasons for 
discontinuation of treatment may include refusal by the subject to receive additional treatment or physician’s decision. The investigator should request that a subject 
discontinuing treatment continue to participate in the study and complete all remaining visits and safety follow -up assessments. For subjects declining  continue d study 
participation after treatment discontinuation, additional information regarding subject withdrawal is provided in Section  9.2.6.2. 
If the subject experiences escalating pain during the Ultherapy procedure that is not adequately controlled with the initially selected treatment regimen, the investigator s may 
use their discretion to utilize further protocol -specific options to control pain 
(Section  10.5.1.2). Attempts should be made to optimiz e pain medication so that treatment 
can be completed . 
9.2.6.2  Subject Withdrawal or Discontinuation 
Each subject will be followed to the end of study, or until  the sponsor decides to terminate 
the study, whichever comes first. The only reasons a subject will not be followed for all 
scheduled visits i nclude withdrawal of consent, continuous non-compliance with protocol 
requirements, or loss to follow -up (e.g., moving away from study site; unresponsive to 
attempts to contact the subject). Additionally, the investigator can discontinue any subject, at any time, if medically necessary.  
Subject s have the right to withdraw from the study at any time at their own request without 
prejudice. In cases of withdrawn consent, data collected until the date consent was 
withdrawn will be analyzed as recorded.  
If a sub ject does not attend a required study visit, the following actions will be taken:  
• The site will attempt to contact the subject at least twice and reschedule the missed visit 
as soon as possible. Every effort to regain contact with the subject will be made (e.g.,  telephone contact on different dates/times, registered mail). All contact attempts 
will be documented.  
• If attempts to contact the subject are not successful, the subject will be considered lost to follow -up and discontinued from the study.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 33 of 89 The reaso n for the subject’s discontinuation should be documented in the electronic case 
report form (eCRF). The investigator should make every attempt to complete the 
recommended follow -up assessments specified for the End of Study/Early Termination 
visit specifie d in the Schedule of Events ( Section  11.1 ), while fully 
respecting the subject’s rights.  
In the case of a reported nerve effect leading to paresthesia or weakness , as well as any 
severe unanticipated AE that is determined to be an AE related to the device treatment, a 
root-cause investigation will be conducted to determine the cause, the outcome of the event , 
and status of subject. The investigator and the sponsor  will conduct a thorough evaluation 
of the event. The sponsor  will then immediately make a determination if the study should 
be suspended (Section 9.2.8). 
If a non-serious AE is unresolved at the time of the subject’s final study visit, an effort will be made to follow  the subject  until the AE is resolved or stabilized, the subject is lost to 
follow -up, or some other resolution of the event  occurs . The investigator should make 
every attempt to follow all serious adverse events (SAEs) and unanticipated adverse device effects (UADEs) to resolution. Information on pregnancy and the outcome for any subject  
who becomes  pregnant during the study will be collected.  
9.2.6.3  Provision of Care for Subjects after Study Discontinuation 
The investigator is responsible for ensuring the adequate and safe medical care of subjects during the study. After the end of the study or after subject discontinuation, the sponsor 
will follow all applicable local or international regulations and guidelines with regard to follow -up care for subjects. The investigator will ensure that appropriate consideration is 
given to a subject’s post -study car e. 
9.2.7  Suspension or Premature Termination of a Study Site  
Study participation by individual sites may be suspended or prematurely terminated by the 
sponsor. Reasons for the suspension or premature termination  of study sites include, but 
are not limited to, the following:  
• Investigator request;  
• Serious or persistent noncompliance with the protocol, local regulations, and/or GCP;  
• Suspicion of fraud;  
• Failure to accrue subjects at an acceptable rate; and/or  
• Ethical  issues.
 
The sponsor will provide the investigationa l site  with written notification documenting the 
reason for suspension or premature termination. The sponsor will inform the responsible 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 34 of 89 regulatory authority, as appropriate, and ensure the IEC/IRB is not ified. If the suspension 
or premature termination was in the interest of safety, the sponsor will inform all other 
principal investigators.  
In cases of temporary suspension at an investigationa l site , the sponsor will conduct an 
analysis of the reason(s) f or suspension. After completing this analysis and implementing 
necessary corrective actions, a temporary site suspension may be lifted. The sponsor will inform the principal investigators, the IEC/IRB, and, where appropriate, the regulatory 
authority of the rationale, providing relevant data supporting this decision. Concurrence must be obtained from the IEC/IRB and, where appropriate, regulatory authorities before the investigationa l site  resumes trial activities. If subjects were informed of the suspensio n, 
the principal investigator or authorized designee will inform them of the reasons for resumption.  
In cases of premature termination, the investigator will conduct site -closure activities in 
accordance with all applicable sponsor, local, and internationa l guidelines and regulations.  
In the event of a pandemic disease outbreak (e.g., new COVID -19 public health 
emergency), it may  not be feasible for a n investigationa l site  to continue study 
participation. In this scenario, consideration will be given to the  impact of investigative -
site closure on the safety and well -being of participating subjects.  
9.2.8  Suspension or Premature Termination of the Study  
Should the investigator, sponsor, the FDA, or local regulatory authorities become aware of conditions arising dur ing the conduct of this study that may warrant cessation of the study, 
such action may be taken. Prior to such action, consultation between the sponsor, the 
investigator, and, as appropriate, the FDA and/or local regulatory authorities will occur.  
Reasons for suspension or premature termination of the study include, but are not limited 
to: 
• Determination of a potential safety risk to subjects;  
• Inadequate subject enrollment;  
• Decision by the IEC/IRB to suspend or terminate approval/favorable opinion for the 
study; and/or  
• Sponsor decision.  
If suspicion of an unacceptable risk to subjects arises during the trial or if instructed by the IEC/IRB or regulatory authorities, the sponsor will suspend the trial while the risk is assessed. If the analysis determines that  implementing necessary corrective actions is 
sufficient, a temporary trial suspension may be lifted. If an unacceptable risk is confirmed, the sponsor will terminate the trial.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 35 of 89 In the event of study suspension or premature termination, the sponsor will inform all 
investigators and relevant regulatory authorities promptly of the study suspension/  
termination and reason for the action, as detailed in Section 9.2.7. The investigator will 
conduct site -closure activities in accordance with all applicable sponsor , local, and 
international guidelines and regulations.  
9.2.9  Subject Completion 
Subjects are considered to have completed the study if  they receive full treatment  and 
complete all visits defined in the Schedule of Events  (Section  11.1 ). 
9.2.10  End of Study  
The end of the study is defined as when the last subject completes the last visit  and the 
database is closed . 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 39 of 89 10.2 Instruc
tions for Use and Administration 
The investigational device should be used in the décolleté region in accord ance with the 
information presented in Section  10.3. Additional information on product us age is 
provided in the current version of the Octave System IFU   
It is recommended that the following areas be avoided during treatment with the Octave 
System : 
• Thyroid gland, thyroid cartilage, and trachea ; 
• Major vessels ; 
• Breast tissue.  
The Octave System should only be used by those trained and qualified to operate. For this 
clinical trial, such training will be provided by the sponsor before the start of the study. Additionally, should study personnel  change during the trial, the sponsor  will retrain, as 
necessary.  
10.3 Methods of Assigning Subjects to Treatment Groups  
Subjects who provide informed consent, complete all screening assessments, meet all eligibility criteria, and are accepted for enrollment into the study will be assigned a unique 
subject identification number.  
CCI
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 43 of 89 
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 44 of 89 10.5.2  Sele
ction and Timing of Treatment for Each Subject  
At the baseline visit, a ll enrolled healthy, adult subjects with moderate to severe fine lines, 
wrinkles, laxity, and crepiness of the décolleté will receive a single Octave-Ultherapy 
treatment of the décolleté tissue according to the treatment guidelines presented in 
Section  10.5.1.3. No additional treatments will be offered under this study protocol.  
10.5.3  Treatment Interruption and Modification 
If any problems occur during system operation, the treating investigator should take the 
following immediate action(s): lift the transducer off the subject’s  skin, press the 
Imaging/Ready button on the handpiece or console  to discontinue treatment in progress, 
and/or press the red emergency Stop button to completely halt console  operation.  
As described in Section  10.5.1.2, should the subject experience escalating pain during the 
Ultherapy procedure that is not adequately controlled with the previously selected 
treatment regimen, the investigator s may use their discretion to utilize further protocol -
specific options to control pain.  If the pain experienced by the subject remains intolerable 
after having administered the maximum allowable limit and type of treatment medications, 
treatment should be discontinued, and the subject will be followed for safety only.  
10.6 Prior and Concomitant Therapy  
Medical history and concomitant therapies , including  pre- and post -treatment pain 
measures, that are deemed rel evant for study conduct by the investigator (e.g., chronic 
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 46 of 89 according to the clinical study protocol. The sponsor will keep records to document the 
physical location of all IMDs from shipment to the investigational sites until return or 
disposal. The investigator or an authorized designee is responsible for ensuring that 
accurate records  of receipt, use, return, and disposal of the IMD, are maintained and 
include:  
• Date of receipt.  
• Identification of each IMD (batch number/serial number or unique code).  
• Expiration date.  
• Date or dates of use.  
• Unique s ubject number . 
• Date of return of unused, expired, or malfunctioning IMD (if applicable).  
All unused investigational products must be returned to the sponsor or designee immediately after the stud y is completed. Products deliberately and/or accidentally 
destroyed during shipment or at an investigationa l site  should be accounted for and 
documented. All clinical supplies must be accounted for at the termination of the study and a written explanation provided for discrepancies.   
Lastly, dispensing records of treatment lines are recorded on the subject’s treatment record, which is automatically generated by the Ulthera System. These data will be entered to the 
EDC system. An overall accountability log w ill be maintained, documenting the number 
of treatment lines per subject.  
10.10  Treatment Compliance  
The single treatment session will be administered by the treating investigator  or by 
delegated and qualified study personne l. Variations from the defined study-t reatment 
administration will be reported as protocol deviations.  See Section  10.5.1.3 for additional 
details.  
10.11  Duration of Study  
Subjects are screened at the screening visit and enrolled and treated at the baseline visit. Expected study duration is approximately 8 months from screening of the first subject until 
final follow -up of the last subject. In Stage  1, an initial cohort of s ubjects will be enrolle d, 
safety data will be assessed up to Week  2, and subjects will participate until Stage  1 study 
end at Day  90. In Stage  2, all enrolled subjects will participate for a t least 90  days 
(± 7 days), with a  maximum duration of 180 days (±  14 days)  if reconsented for extended 
participation . The planned duration of participation for individual subjects is up to 
30 weeks, including up to 21 days for screening, 1 day for treatment, and 90 (± 7) days or 
180 (± 14) days for follow -up.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 50 of 89 After removing any moisturizers/emollients, makeup, bronzing agent s, etc. on the 
neck/décolleté regi on, these untreated individuals will be required to meet selected 
appearance criteria as follows:  
• Female aged 35 to 65 years.  
• Moderate to severe fine lines, wrinkles, laxity, and crepiness of the décolleté that is 
amenable to improvement with non-invasive intervention and is not severe enough for 
surgical intervention. 
• No scarring in the décolleté region . 
• No tattoos in the décolleté region . 
• No open wounds or lesions in the décolleté region . 
• No active, cystic, or severe inflammatory acne in  the décolleté reg ion. 
• No evidence of recent excessive or prolonged exposure to sunlight, tanning booths, sun 
lamps, or UV -light sources in the décolleté region . 
• No evidence of recent use of pigmenting agents ( e.g., self-tanning agents, 
bleaching/depigmenting agents) in the  décolleté region . 
• No evidence of recent medical procedures in the  neck, breast, shoulder, arm, or chest 
region.  
• Willingness to avoid excessive or prolonged exposure to sunlight, tanning booths, sun lamps, or UV -light sources until second photo is taken.  
• Willingness to avoid the use of pigmenting agents ( e.g., self-tanning agents, 
bleaching/depigmenting agents) until second photo is taken.  
• Willingness to avoid any elective neck, breast, shoulder, arm, or chest surgery, 
procedure , or treatment until after th e second photo is taken.  
Untreated individuals will be screened and selected by a third-party vendor, responsible 
for conducting all photography services . Eligibility of untreated individuals  will be based 
on study-specific appearance only , as listed above , and will be confirmed by the sponsor’s 
medical expert. Photographs of untreated individuals will be taken at two different time points , between 1 day and 1 week apart.  
Additional information on the methodological plan, detailing photograph collection 
through subsequent presentation to blinded evaluators , will be provided in a supporting 
document, developed collaboratively between the sponsor and the photography vendor.  
Results of the independent photographic review for the untreated individuals  will be 
recorded.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 51 of 89 11.2.1.1.2  Photographs for Independent, Blinded Evaluation 
To assess t he proportion of treated subjects with improvement in lines and wrinkles of the 
décolleté from baseline to Day 90 (i.e., primary effectiveness endpoint)  and to Day 180 
(i.e., secondary effectiveness endpoint), three independent, blinded evaluators will assess 
paired, 2D photograph sets of treated subjects and untreated individua ls , according to t he 
procedure described below . These  evaluators  will be e xperienced, non-treating physicians,  
who are board-certified in an appropriate specialty (e.g., dermatology, plastic surgery, etc.).  
One image set , containing only the frontal view,  will be paired as follows: 
• Set 1 (treated subjects only): Photograph 1 (baseline) vs. Photograph 2 ( Day 90 or 
Day 180 post-treatment); 
• Set 2 (untreated individuals only): Photograph 1 (“baseline”) vs. Photograph 2 (post -
baseline).  
Photograph 1 will be identified , and the independent evaluators  will be blinded to the 
random distribution of treated versus untreated status of the comparator Photograph 2 (i.e., 
Day 90 or Day 180 post -treatment among treated subjects or post -baseline  for untreated 
individuals) . 
For each image set, blinded evaluators will assess each p hotograph and will be asked the 
following: “Using Photograph 1 as a reference, which of the following best characterizes 
the change in aesthetic appearance observed in the comparator Photograph 2 : Improvement 
or No Improvement.”  
Improvement will be declare d if at least two blinded evaluators indicate “Improvement” 
for the comparator photograph.  
Additional information on the methodological plan, detailing photograph collection 
through subsequent presentation to blinded evaluators , will be provided in a supporting 
document, developed collaboratively between the sponsor and the photography vendor.  
This assessment will be proctored by the central photography vendor . 
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 52 of 89 11.2.2  Safet
y Assessments 
Standard safety assessments, including documentation of AEs and SAEs reported by the 
investigator throughout the study, will be evaluated.  
11.2.2.1  A
dverse Events  (AEs)/Serious Adverse Events (SAEs) 
All AEs /SAEs  reported by study subjects, investigators, or other study personnel  after the 
time of informed consent through end of study will be recorded , regardless of causality.  
The period of observation for an AE extends from signing of the ICF through the subject’s 
last stu dy visit. Additional information (e.g., definitions, reporting requirements) regarding 
AEs and SAEs is provided in Section  12.1 and Section  12.2, respectively.  
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 53 of 89 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 54 of 89 11.2.3  Additiona
l Data Collected 
Data for other assessments will be collected as follows:  
• Demographics and other baseline characteristics , including FST , 
height , and weight ; 
                                                             
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 55 of 89 • Urine pregnancy tests (only if subject is of childbearing potential);  
• Number of treatment lines administered, stratified by region and transducer ; 
• Relevant medical histor y/concomitant diseases; and 
• Concomitant therapies . 

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 56 of 89 12 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
12.1 Definition of an Adverse Event (AE) 
An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical sign (including abnormal laboratory findings) in subjects, users , or other persons, 
whether or not related to the IMD.  
Note:  
1. This definition includes events related to the IMD . 
2. This definition includes events related to the procedure s involved.  
3. For users or other persons, this definition is restricted to events related to the IMD . 
12.1.1  Details of an AE 
The period of observation for an AE extends from when the ICF i s signed until the subject’s 
last study visit. Any medical occurrence between the time the ICF is signed and the first 
treatment with the IMD is an AE and has to be documented in the subject’s file and in the 
AE eCRF . Any observed AE will be fully investigated, documented, and followed until the 
event is either resolved or adequat ely explained. In cases of surgical or diagnostic 
procedures, the condition/illness leading to such a procedure is considered the AE rather 
than the procedure itself. New AEs reported to the investigator during the observational period, after the last treatment with the IMD, must be documented, treated, and followed like all other AEs.  
A pre-existing condition noted in the medical history should not be reported as an AE, 
unless the condition worsens or the disease reoccurs during the reporting period. To determine whether a condition has worsened, it is compared to the subject ’s condition 
at screening.  
Elective treatments planned before screening, and which are documented in the subject’s source data, are usually not regarded as AEs. However, elective procedures should be postponed, if possible, until the subject completes participation in the trial.  
12.1.2  R eporting and Handling of an AE 
Data pertaining to AEs will be collected during each clinical study visit based on the subject’s spontaneous description, through investigator inquiry, or upon discover y in the 
course of examinations completed during the visit. The investigator will assess and record 
any AE in detail in the subject file  and on the AE eCRF. The following information must 
be recorded:  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 57 of 89 • AE diagnosis or main symptom ; 
• Affected  treatment area. In case o f a local reaction, the corresponding area should be 
reported; 
• Date of onset ; 
• Intensity (maximum observed using the  Severity  Grading scale ; see Section  12.1.3); 
• Causal relationship (not related, related) ; 
• Serious (yes or no) , date serious since, and reason for seriousness ; 
• Outcome (see Section  12.1.5); 
• AE leading to discontinuation of the clinical study (yes or no) ;  
• Action taken with medical device; and 
• Stop date.  
In cases of an SAE  (defined in Section  12.2), the investigator must also complete an SAE 
Report Form and report it to the sponsor within 24 hours , as described in Section  12.2.2. 
12.1.3  Severity Grading for an AE 
The clinical severity  (i.e., intensity ) of an AE will be classified as: 
Mild:  Signs and symptoms that can be easily tolerated. Symptoms can be ignored 
and disappear when the subject is distracted.  
Mode rate:  Signs and symptoms that cause discomfort and interfere with normal 
functioning but are tolerable. They cannot be ignored and do not disappear when the subject is distracted.  
Sever e:  Signs and symptoms that affect usual daily activity and incapacitate the 
subject, thereby interrupting daily activities.  
The investigator is required to grade the severity (i.e., intensity ) of each AE.  
12.1.4  Causal Relationship of an AE with an Investigational M edical 
Device 
An AE is considered to be “related” to IMD or the treatment  procedure if a causal 
relationship between the IMD or the treatment  procedure and an AE is at least reasonably 
possible. In this case , the non-serious event is considered an adverse device effect ( ADE; 
Section  12.3). If the event is serious , it is a serious adverse device effect ( SADE; 
Section  12.4). 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 58 of 89 The expression “reasonable causal relationship” is meant to convey that there are facts 
(evidence) or arguments to suggest a causal relationship. Otherwise, the relationship should 
be considered as “not related”.  
12.1.5  Outcome Categories for an AE 
Reportable outcomes and/or sequelae of an AE may include the following : 
• Recovered/resolved ; 
• Recovering/resolving; 
• Not recovered/not resolved; 
• Recovered/resolved with sequelae ; 
• Fatal ; or 
• Unknown.  
If there is more than one AE, only the AE leading to death will be attributed with a “fatal” 
outcome.  
12.2 Definition of a Serious Adverse Event (SAE ) 
An SAE is an adverse event that:  
• led to death;  
• led to serious deterioration in the health of the subject, that either resulted in: 
o a life-threatening illness or injury; 
o a permanent impairment of a body structure or a body function, including 
chronic diseases ; 
o inpatient or prolonged hospitalization ; or 
o medical or surgical intervention to prevent life -threatening illness or inj ury or 
permanent impairment to a body structure or a body function.  
• led to fetal distress, fetal death, or a congenital abnormality or birth defect  including 
physical or mental impairment . 
Note: Planned hospitalization for a pre -existing condition, or a pr ocedure required by the 
clinical study protocol ( CSP), without serious deterioration in health, is not considered a n 
SAE. 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 59 of 89 12.2.1  Details of an SAE 
In cases of fatality, the cause of death is considered the AE , and the death is considered its 
outcome. In this case , the primary cause of death ( i.e., the event leading to death) should 
be recorded and reported as an SAE. “Death” will be recorded as the outcome of this 
respective event; death will not be recorded as a separate event. Only if no cause of death can be reported (e.g., sudden death, unexplained death), the death per se  might be reported 
as an SAE. In cases of death, an autopsy report should be submitted (if available). The date and cause of death should be recorded.  
Planned hospitalization for a pre -existin g condition is not considered an SAE. If a subject 
experiences an additional AE that prolongs a pre -planned hospitalization, this event is  
considered an SAE and should be reported as such. Hospitalizations for elective treatments 
planned before screening a nd which are documented in the subject’s source data are not 
regarded as SAEs.  
In addition, device deficiencies , as defined in Section  12.5, that might have led to an SAE 
if: 
• suitable action had not been taken; or  
• intervention had not been made ; or 
• if circumstances had been less fortunate 
should be categorized as an SAE and reported accordingly.  
12.2.2  Reporting and Handling of an SAE 
All SAEs that occur during the clinical study period, whether considered to be related to an IMD or not, must be reported via telephone or e -mail, and an SAE Report Form should 
be submitted to the sponsor immediately  of knowledge of the event. Further  reporting 
details will be outlined in a sepa rate document.  
Although all information required for completion of an SAE Report Form may not be 
available within the specified time period, an initial report should be submitted if the following minimal information is available: 
• An identifiable subject ( unique subject number) ; 
• A suspect product and how the treatment relates to the SAE ; 
• An identifiable reporting source (investigator/study site identification) ; and/or  
• An event or outcome that can be identified as serious.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 60 of 89 The investigator must report SAEs to Merz as defined in Section  12.2 and the site’s 
IEC/IRB per their reporting guidelines.  
Within 10 working days after Merz first receives notice of the SAE, Merz Product Safety 
will conduct an evaluation of the SAE and report the results of such evaluation to regulatory agencies, IECs/IRBs , and investigators, as applicable.  
The investigator must supply further supporting information, and a detailed SAE 
description is an integral part of this supporting information. Follow -up SAE reports should 
be sent without delay to the sponsor as an SAE Report Form (marked as  a “follow -up” 
report) , and the e CRF has to be updated accordingly to avoid discrepancies . The SAE  has 
to be followed until the SAE is resolved/recovered or a plausible explanation is available.  
The SAE will be followed only in the Global Product Safety database after final SAE 
reconcilia tion is completed.  
An SAE occurring after the end of the observational period would need to be reported if 
the investigator considers the event to be related to IMD . These reports generally will not 
be entered into the study database. Following database  close for the study, any ongoing 
SAEs  will be followed until resolution or stabilization under the responsibility of the 
investigator s per their standard of care.  
The investigator should complete and send any SAE Report Forms (including any follow -
up forms) to Merz North America Product Safety via the email provided below:  
Merz North America, Inc. Product Safety  
6501 Six Forks Road 
Raleigh, NC 27615 US 
Product Safety Email : AxUS -adverse.events@merz.com  
12.3 Definition of an Adverse Device Effect (ADE ) 
An ADE is defined as an AE  related to the use of an  IMD . 
Note:  
1. This definition includes AEs resulting from insufficient or inadequate instructions 
for use, deployment, implantation, installation, or operation or any malfunction of 
the IMD . 
2. This definition includes any event resulting from use error or from intentional 
misuse of the IMD . 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 61 of 89 12.4 Definition of a Serious Adverse Device Effect (SADE ) 
A SADE is defined as an adverse device effect that has resulted in any of the consequences 
characteristic of an SAE ( Section  12.2). 
12.4.1  Definition of an Anticipated Serious Adverse Device Effect 
(ASADE ) 
An ASADE is a serious adverse device effect which by its nature, incidence, severity , or 
outcome has been identified in the current version of the risk analysis  report.  
12.4.2  Definition of an Unanticipated A dverse Device Effect (UADE ) 
A UADE is defined as follows:  
• Any serious adverse effect on health or safety or any life -threatening problem or death 
caused by, or associated with, a device, if that effect, problem, or death was not 
previously identified in nature, severity, or degree of incidence in the investigatio na l 
plan or application (including a supplementary plan or application), risk analysis report, 
or IFU.  
• Any other unanticipated serious problem associated wit h a device that relates to the 
rights, safety, or welfare of subjects.  
12.5 Definition of Device Deficiency  
A device deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performanc e. 
Note: Device deficiencies include malfunctions, use errors, and inadequate labeling.  
12.6 Definition of Technical Complaint  
A technical complaint, also referred to as a product complaint, is an apparent or suspected 
deficiency of a product in which the product does not meet its specification (e.g., console 
error, transducer failure, handpiece malfunction). 
Note: The term “ technical complaint ” is synonymous with the term “ device deficiency ”. 
The term device deficiency is used in this study.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 62 of 89 12.6.1  Reporting and Handling of D evice Deficiencies  
All device deficiencies shall be documented and reported by the investigator throughout 
the clinical investigation and appropriately reported to the sponsor . 
For reporting of device deficiencies:  
• For device deficiencies related to a specific subject’s treatment, a Device Deficiency 
eCRF must be completed and submitted by the investigati onal site, irrespective of the 
seriousness of the case.  
• For device deficiencies related to a specific subject’s treatment, a Device Defici ency 
eCRF must be completed and submitted by the investigati onal site, irrespective of 
whether the complaint led to an AE. The investigator will attempt to evaluate if the device deficiency might have led to an AE if suitable action had not been taken, 
intervention had not been made, or circumstances had been less fortunate.  
• If a device deficiency is associated with an SAE, the investigator  must also complete 
and submit an SAE Report Form ( Section  12.2.2), in addition to the Device Deficiency 
eCRF . SAE Report Forms should be sent to Merz Product Safety  for processing 
(Section  12.2.2). 
• If a device deficiency is not related to a specific subject (e.g., damaged transducer or 
handpiece occurring prior to the subject’s visit), the investigator should complete a paper device deficiency form (e.g., Devi ce Technical Complaint Form), instead of the 
eCRF, and send to the sponsor within 24 hours to both their clinical study representative as well as to the Merz Technical Complaint Department for processing using the 
following email address: devicehelp@merz.com . If needed, technical complaint 
support can be reached at 877-858-4372. 
The investigator should retain the device in question for future inspection and investigation 
by the sponsor, if necessary. The Merz Technical Complaint Department will decide if the 
device in question needs to be returned and to whom it should be sent for investigation.  

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 63 of 89 12.8 Report
ing of Pregnancy  
Any pregnancy that starts during the clinical study must be reported by the investigator to 
the sponsor within 24 hours of l earning of its occurrence. Pregnancy follow -up should 
describe the outcome of the pregnancy, including any voluntary or spontaneous 
discontinuation; details of the birth; the presence or absence of any congenital 
abnormalities, birth defects, maternal or n ewborn complications, and their relation to the 
IMD. Pregnancies and pregnancy follow -up should be reported on a Pregnancy Form ; this 
form should be submitted to the contacts referenced in Section  12.2.2. In addition, each 
pregnancy has to be reported on the AE eCRF (i.e., as a non-serious AE due to device exposure before or during pregnancy).  If subject s become pregnant during the study, they 
will remain enrolled for safety follow -up.  

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 64 of 89 13 STATISTICAL METHODS 
This section describes the statistical analyses foreseen at the time of study planning. Further 
details on the statistical and analytical aspects will be presented in the statistical analysis  
plan (SAP) that will be prepared and completed prior to interim closure of the study 
database.  If needed, the SAP will be updated before database close at the end of the study.  
Any deviations from planned analyses, the reasons for such deviation, and all alternative 
or additional statistical analyses that may be performed before database close will be 
described in amendments to the clinical study protocol and/or the SAP. All deviations 
and/or alterations will also be summarized in the clinical study report . 
13.1 Estimation of Sample Size 
A responder rate of 70% is assumed for the proportion of subjects with improvement from 
baseline to Day 90, as defined by the correct  selecti on of the Day 90 standardized, 
photographic  images by two of three independent, blinded evaluators . Monte -Carlo 
simulations were conducted to obtain sample sizes of evaluable subjects required to achieve an improvement  rate of ≥ 65% and lower bound of 1-sided 95% confidence 
interval above 50%. To achieve this threshold with ≥ 85% power , a sa mple size of 80 
evaluable subjects will be required. Assuming a maximum attrition of 10 subjects, approximately 90 subjects will be enrolled. In Stage  1, 10 subjects will be enrolled , while  
all other subjects will be enrolled  in Stage  2. Because a sample s ize of 80 subjects who 
complete the full Ultherapy treatment session is required, study enrollment will continue 
until the required number of treated subjects is achieved.  
13.2 Randomization 
No randomization procedures for treatment allocation will be used in this study.  
13.3 Populations for Analysis  
The following analysis sets will be defined for the statistical analysis of this study:  
• The Safety Population (SP) includes all subjects who are enrolled and are treated  with 
the Octave System.  
• The Intent -to-Treat (ITT) population consists of all subjects who are enrolled . 
• The Per Protocol (PP) population consists of all subjects in the ITT population who complete the full Ultherapy treatment session using t he Octave System and do not have 
a majo r protocol violation.  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 66 of 89 Gain or loss of ≥ 2 BMI units from screening to Day 90 will be considered a major protocol 
deviation. Subjects with gain or loss of ≥ 2 BMI units from screening to Day 90 will be 
excluded from PP population. The following subgroups will be defined by the change in 
body weight from s creening to Day 90:  
• Subjects in ITT population with gain of ≥ 2 BMI units ; 
• Subjects in ITT population with loss of ≥ 2 BMI units ; and 
• Subjects in ITT population with change of < 2 BMI units . 
Primary endpoint with observed cases will be analyzed in all subgroups , as defined above , 
with more than five  subjects.  
13.4.1.2  Secondary Effectiveness Endpoint  
Note: Secondary endpoint will be assessed only among subjects reconsented for extended 
study participation. 
The proportion of subjects fulfilling the secondary endpoint will be described by frequency 
statistics for the ITT subset, including the one -sided 95% Wilson CI . 
13.4.2  Safety Analyses 
All safety evaluations will be summarized for observed values in the SP.  
CCI

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 67 of 89 13.4.2.1  Secondary Safety Endpoint  
All AEs will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA ) version in effect at the time the database is closed.  
Treatment -emergent AEs (TEAEs) are defined as AEs with onset or worsening at or aft er 
the first administration of study treatment. In this regard, an AE, with onset prior to 
treatment, that worsens at or after first administration of study treatment must be 
documented as a new TEAE with onset at the time of worsening.  
An overall summary of AEs will be provided for the following:  
• Any AEs;  
• Any non-TEAEs; 
• Any TEAEs; 
• Any treatment -related TEAEs; 
• Any serious TEAEs, and 
• Any TEAEs leading to discontinuation.  
Incidences will be provided for the following classes of AEs:  
• TEAEs by MedDRA preferred term (PT) and system organ class (SOC);  
• TEAEs by PT; 
• TEAEs by maximum severity, maximum duration, and combination of both by PT;  
• Related TEAEs by PT and SOC; and 
• Serious TE AEs by PT and SOC , 
• Related serious TEAEs by PT and SOC . 
Moreover, incidences of TEAE s, by PT and SOC , will be provided for the following 
subgroups:  Race and  FST (I, II, III versus IV, V, VI).  
Listings for all AEs, as well as subsets including AEs leading to discontinuation , related 
SAEs,  and deaths , will be provided.  Treatments discontinued due to pain and device 
deficiencies will also be listed . 
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 68 of 89 13.4.3  Oth
er Subject Data 
All demographic, baseline characteristics, and s ubject disposition data will be presented 
using standard descriptive statistics. Demographic data will be summarized for the  SP and 
also for the ITT subset if differences exist between the two populations . 
Frequencies of concomitant treatments will be given based on different Anatomical 
Therapeutic Chemical (ATC) Classification System code levels for the SP . Indications  for 
concom itant therapies will not be coded and will only be listed.  
Medical history and concomitant diseases will be  coded using the MedDRA dictionary and 
reported by SOC and PT levels for the SP.  Extent of exposure (lines applied by region and 
transducer) will be summarized.  
CCI
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 69 of 89 13.5 Special Statistical/Analytical Issues  
13.5.1  Subject Discontinuation and Missing Data 
The methods intended for handling a missing primary or secondary effectiveness endpoint 
are described in Section  13.4.1.1 and Section  13.4.1.2, respectively . 
 
For the remaining endpoints, observed cases will be analyzed,  unless otherwise specified.  
13.5.2  Interim Analysis 
In Stage  1, an initial cohort of 10 subjects will be enrolled. An inter im database close and 
interim safety analysis of the first 10 subjects treated  in Stage  1 will be conducted. This 
Stage  1 analysis will contain Week  2 safety data for the first 10 subjects treated . Safety 
analyses will be performed on the S P. Effectiveness  data will not be included in the interim 
analysis.  
Continuation to Stage 2 will be paused during evaluation of the Week  2 safety data from 
the first 10 subjects treated.  All 10 subjects enrolled in Stage  1 will participate until Stage  1 
study end, for a maximum duration of 90 days (±  7 days).  
The interim analysis is only intended to obtain safety data for the first 10 subjects treated 
before starting recruitment for Stage  2. The interim analysis is not proposed to modify the 
study design, statistical anal yses, or sample size, or for study termination, as this is not an 
adaptive study design. Since no effectiveness data are analyzed at interim, the interim analysis will not compromise the integrity of the study’s effectiveness data, and it will not bias the  final effectiveness analysis.   

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 70 of 89 14 ADMINISTRATIVE PROCEDURES 
14.1 Study Monitoring 
Study monitoring will conform to all applicable regulatory standards and guidelines.  
The sponsor or designee will monitor the study through periodic site visits to verify:  
• Data authenticity, accuracy, and completeness ; 
• Protection of subject rights and safety; and 
• Conduct of the study is in accordance with the currently approved protocol and all 
applicatory regulatory requirements and guidelines.  
Investigators agree to grant acces s to all relevant documents and provide support at all 
times for study monitoring activities. Study monitoring activities will be performed in a manner that ensures maintenance of subject confidentiality ( Section  5.3 and Section 5.4). 
Further details of monitoring activities will be described in the monitoring manual.  
14.2 Data Quality Assurance  
Inspections by regulatory authority representatives and IECs/IRBs are possible at any time, even after the end of study. The investigator is to notify the sponsor immediately of any such inspection. The investigator and insti tution will permit study-related monitoring , 
audits, reviews by the IEC/IRB and/or regulatory authorities, and will allow direct access to source data and source documents for such monitoring, audits, and reviews.  
14.2.1  Standardization Procedures 
Standardization procedures will be implemented to ensure accurate, consistent, complete, 
and reliable data, including methods to ensure standardization among sites (e.g., training, newsletters, investigator meetings, monitoring, evaluations, and validation methods).  
Standardized photography methods will be detailed in a separate photography user manual.  
This study will be monitored regularly by a qualified monitor from the CRO according to 
GCP guidelines and the respective standard operating procedures (SOPs ; see Section  14.1). 
14.2.2  Data Management  
Data required according to this protocol are to be recorded in the web-based eCRFs 
provided by a CRO. All users who will enter data into the eCRF must successfully 
complete  training  before system access is granted. P articipant training will be documented . 
Access to the eCRF will be  password  controlled and will conform with 21 CFR Part 11 . 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 71 of 89 Data -plausibility checks will be performed according to a data validation plan. 
Inconsistencies in the data will be queried to the investigators via the EDC system; answers 
to queries or changes to the data will also be documented in this system directly by an 
authorized member of the investigat or’s study personnel. The audit trail in the EDC  system 
will document all changes. Edit checks generate automatic queries during data entry when 
a field is not populated according to specifications defined in the data validation plan. 
Manual queries to be answered by study personnel  can be raised during source data 
verification and/or during medical , safety , and/or  data management review.  
Photographs will be archived by the central photography vendor in a system separate from 
the database (see Section  14.3). photo ratings by 
independent,  blinded investigators  will be transferred electronically to the data 
management CRO . Checks will be performed to ensure plausibility  and completeness of 
these  data. The data management activities and photograph processing will be delegated to 
 CRO s  
After all necessary data for the interim safety analysis of the first 10 subjects enrolled in 
Stage  1 have been entered and cleaned, an interim database close will be performed.  
The database will be closed after all subjects have completed their Day 90 visit and again 
after completion  of their Day 180 visit. Hence, after all applicable data are entered, 
monitored, and verified, and all queries are solved, the database will be closed. After 
database close at D ay 90, the relevant pages will remain locked for further data entry and/or 
update. I f data changes are needed  after database close, they will be documented according 
to the respective SOP. The same requirements apply for the D ay 180 database lock. 
For the final analysis, after all data are entered and all queries are resolved, the d atabase 
will be closed again.  If any data changes are required after database close, these changes 
will be documented according to the respective SOP.  
Further details of the data management process will be described in the data management 
plan. 
14.2.3  Data Review  and Clarification Procedures  
By electronically signing  the eCRF  with an automated time stamp, the investigat or will 
confirm that all investigations  have been completed and conducted in compliance with the 
CSP and that reliable and complete data have been entered into the eCRF . 
All data required by this CSP are to be recorded in the eCRF as soon as possible. However, 
direct entries are not allowed; data must be transcribed from the source documentation 
(e.g., s ubject file, scales) to the eCRF.  

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 72 of 89 All data  required by this study protocol , except  photography ratings , are 
to be entered into a sponsor -validated database of eCRFs.  
If corrections are necessary, an authorized member of the investigator’s study personnel  
will enter the correct data into the web -based eCRF. The audit trail in the EDC  system 
documents all changes.  
The CRO  and sponsor’s data management function will be re sponsible for data processing, 
in accordance with the CRO ’s and sponsor’s data management procedures. Database close 
will occur only after quality assurance procedures have been completed.  
Entries from questionnaires completed by the subject will be entere d into the eCRF by 
study personnel . If corrections in the questionnaires  are necessary, the subject should be 
instructed to make a correction by drawing only a single line through the error, leaving the 
incorrect entry legible. The subject should date and initial the correction. T he investigator 
should not make any changes to these documents.  
14.2.4  Auditing 
To ensure compliance with applicable standards and regulations, the sponsor, IEC/IRB, or regulatory authorities may conduct a quality assurance assessment or audit of site records at any time during or after completion of the study. In the event of an audit, investigators must grant access to all relevant documents (including source documents, electronic 
records, and other applicable study documentation) and pr ovide support at all times for 
auditing activities.  
14.3 Record Retention 
Essential documents should be retained per applicable regulations and as instructed by the study sponsor. Essential documents at the investigational site include but are not limited 
to: 
• Source documentation (e.g., s ubject files ); 
• Subject identification code list  (i.e., provided by template to the investigator, along with 
the Investigator Site File, at the beginning of the investigation), which identifies the 
subject by number, name, and date of birth; 
• A copy of the study protocol and any amendments ; 
• A CD/DVD with eCRF data and any associated subject -related source data (or, where 
applicable, authorized copies of source data) ; 
• Signed ICFs ; 
• Copies of site investigators’ and co-workers ’ curricula vitae;  

Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 73 of 89 • Copies of all direct correspondence with the IEC/IRB and with the regulatory 
authority(ies) ; 
• Copies of all relevant correspondence between the investigator and the monitor, and between the investigator and the sponsor ; 
• Copies of any photographs; 
• Copies of IMD receipt forms and device inventory forms;  and 
• Copies of safety information reported during the investigation and submitted by the sponsor . 
Study documents may not be destroyed by study-site personnel prior to the end of the 
required retent ion period as specified by local regulations. The investigator  or the 
institution must inform the sponsor in due time if the investigator  leaves the institution 
during the retention period. This rule also applies when the institution closes within the 
retention period.  
Upon closure of the study, the investigator must maintain all study-site records in a safe and secure location. The investigator is responsible for the integrity, retention, and security of all study-related records. The investigator must ensure that any reproductions of the original records are legible and provide a true and accurate copy of the original. Accurate, 
complete, and current records must be stored in such a way as to permit easy and timely 
retrieval for the sponsor or any applicable regulatory authorities.  
The sponsor will inform the investigator of the time period for retaining these records to comply with all applicable regulatory requirements, with the minimum retention time being 
the longest of those times dictated by instituti onal requirements, local laws or regulations, 
or the sponsor’s standard procedures. The investigator must notify the sponsor in the event 
of any changes to archival arrangements due to withdrawal of the investigator’s responsibility for keeping study recor ds to ensure that suitable arrangements for the 
retention of study records are made.  
14.4 Publication Policy  
The results of this study and any discoveries related to this study, regardless of whether 
they have technical or medical character, are the property of  the sponsor . 
The CSP, study data, and information related to the study or the sponsor’s products or 
research programs are to be kept confidential and may not be disclosed without the consent of the sponsor.  
The investigator agrees that the results of this study may be used for submission to national 
or international registration and supervising authorities. The sponsor may disclose the 
information obtained during the study to regulatory authorities or other personnel as 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 74 of 89 required. If necessary, the sponsor may disclose the names, contact information, and 
qualifications of all investigators as well as their roles in the study. Upon completion of the 
study, publication or disclosure of the study results is to fol low the terms contained in the 
sponsor’s SOP. 
The sponsor will ensure that a description of this clinical study is registered, and study 
results are disclosed on http://www.Clinica lTr ia ls.gov , as required by US  law. Study 
registration may include a list of study sites, as applicable . 
14.5 Financial Disclosure  
The US FDA Financial Disclosure by Clinical Investigators (21 CFR 54) regulations 
require sponsors to obtain certain financial information from investigators pa rticipating in 
covered clinical studies. By participating in the study, the investigator agrees to provide the required financial information and to promptly update the sponsor with any relevant changes to this financial information throughout the course of the study and for up to one year after its completion if necessary.  
14.6 Investigator Compliance  
The investigator will conduct the study in compliance with the protocol provided by the sponsor and in accordance with all relevant regulatory guidelines and requirements.  
Modifications to the protocol should not be made without the agreement of the investigator 
and sponsor. The sponsor will submit all protocol modifications to the appropriate 
regulatory authority in accordance with applicable regulations. All protocol modifications require written IEC/IRB approval /favorable opinion , except in the case of an immediate 
hazard to subjects.  
If an immediate deviation from the protocol is required to eliminate an immediate hazard to subjects, the investigator must contac t the sponsor or assigned CRO, if possible, to 
discuss the planned course of action. The investigator must thoroughly document any departure from the protocol and submit appropriate documentation to the sponsor without 
delay.   
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 75 of 89 15 REFERENCES 
1. Casabona G, Nogueira Teixeira D. Microfocused ultrasound in combination with 
diluted calcium hydroxylapatite for improving skin laxity and the appearance of lines 
in the neck and decolletage. J Cosmet Dermatol. 2018;17(1):66-72.  
2. Peterson JD, Goldman MP. Rejuvenation of the aging chest: a review and our 
experience. Dermatol Surg. 2011;37(5):555- 71. 
3. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J. Variations of hair follicle size and distribution in different body sites. J Inve st Dermatol. 
2004;122(1):14- 9. 
4. Fitzgerald R, Vleggaar D. Using poly-L-lactic acid (PLLA) to mimic volume in 
multiple tissue layers. J Drugs Dermatol. 2009;8(10 Suppl):s5-14.  
5. Vanaman M, Fabi SG. Decolletage: Regional Approaches with Injectable Fillers . Plast 
Reconstr Surg. 2015;136(5 Suppl):276s -81s. 
6. Sadick N. Tissue tightening technologies: fact or fiction. Aesthet Surg J. 2008;28(2):180- 8. 
7. Oni G, Hoxworth R, Teotia S, Brown S, Kenkel JM. Evaluation of a microfocused ultrasound system for improving skin laxity and tightening in the lower face. Aesthet Surg J. 2014;34(7):1099- 110. 
8. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. 
Arch Dermatol . 1988;124(6):869-71.  
9. Harris MO, Sundaram HA. Safety of microfo cused ultrasound with visualization in 
patients with Fitzpatrick skin phototypes III to VI. JAMA Facial Plast Surg. 
2015;17(5):355- 7. 
10. Hitchcock TM, Dobke MK. Review of the safety profile for microfocused ultrasound with visualization. J Cosmet Dermatol. 2014;13(4):329- 35. 
11. Kaidbey KH, Agin PP, Sayre RM, Kligman AM. Photoprotection by melanin--a comparison of black and Caucasian skin. J Am Acad Dermatol. 1979;1(3):249-60.  
12. Montagna W, Prota G, Kenney J. The structure of black skin. In: Montagna W, Prota 
G, Kenney J, editors. Black Skin Structure and Function: Gulf Professional 
Publishing; 1993.  
13. Taylor SC. Skin of color: biology, structure, function, and implications for 
dermatologic disease. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S41 -62. 
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 76 of 89 14. Vashi NA, de Castro Maymone MB, Kundu RV. Aging Differences in Ethnic Skin. J 
Clin Aesthet Dermatol. 2016;9(1):31-8.  
15. Fabi SG. Noninvasive skin tightening: focus on new ultrasound techniques. Clin Cosmet Investig Dermatol. 2015;8:47-52.  
16. Gliklich RE, White WM, Slayton MH, Barthe PG, Makin IR. Clinical pilot study of intense ultrasound therapy to deep dermal facial skin and subcutaneous tissues. Arch 
Facial Plast Surg. 2007;9(2):88- 95. 
17. Alam M, White LE, Martin N, Witherspoon J, Yoo S, West  DP. Ultrasound tightening 
of facial and neck skin: a rater -blinded prospective cohort study. J Am Acad Dermatol. 
2010;62(2):262- 9. 
18. Fabi SG, Massaki A, Eimpunth S, Pogoda J, Goldman MP. Evaluation of 
microfocused ultrasound with visualization for lifting, tightening, and wrinkle 
reduction of the decolletage. J Am Acad Dermatol. 2013;69(6):965- 71. 
19. Fabi SG, Goldman MP, Dayan SH, Gold MH, Kilmer SL, Hornfeldt CS. A prospective 
multicenter pilot study of the safety and efficacy of microfocused ultr asound with 
visualization for improving lines and wrinkles of the decollete. Dermatol Surg. 
2015;41(3):327- 35. 
20. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog 
Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NR S Pain), McGill Pain 
Questionnaire (MPQ), Short -Form McGill Pain Questionnaire (SF -MPQ), Chronic 
Pain Grade Scale (CPGS), Short Form -36 Bodily Pain Scale (SF -36 BPS), and 
Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S240-52.  
  
Merz North America, Inc.  CLINICAL STUDY PROTOCOL  
M960101003  V ersion 5.0, 22-JUL-2021 
CONFIDENTIAL  AND PROPRIETARY  Page 77 of 89 16 APPENDICES 